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Abstract
Bone marrow derived mesenchymal stem cells (MSCs) 
have immunomodulatory and trophic capacities. For 
therapeutic application in local chronic inflammatory 
diseases, MSCs, preferably of allogeneic origin, have 
to retain immunomodulatory properties. This might be 
achieved by encapsulation of MSCs in a biomaterial that 
protects them from the host immune system. Most studies 
investigating the properties of MSCs for therapeutic 
application use short term cultures of cells in monolayer. 
Since the physical environment of MSCs can influence their 
functionality, we evaluated the feasibility of preserving the 
immunomodulatory properties of MSCs encapsulated in a 
three-dimensional alginate construct.
 After 5 weeks of implantation in immunocompetent 
rats, active allogeneic MSCs encapsulated in alginate 
were still detectable by Bio Luminescence Imaging and 
Magnetic Resonance Imaging of luciferase transduced 
and superparamagnetic iron oxide labelled MSCs. MSCs 
injected in saline were only detectable up to 1 week after 
injection. Moreover, the MSCs encapsulated in alginate 
responded to inflammatory stimuli similarly to MSCs 
in monolayer culture. In addition, MSC-alginate beads 
secreted immunomodulatory and trophic factors and 
inhibited T-cell proliferation after 30 d of in vitro culture. 
Our data indicate that allogeneic MSCs encapsulated in 
alginate persist locally and could act as an interactive 
immunomodulatory or trophic factor release system 
for several weeks, making this an interesting system 
to investigate for application in inflammatory disease 
conditions.
Keywords: Mesenchymal stem cells, alginate, construct, 
encapsulation, cell therapy, immunomodulation.
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Introduction
Mesenchymal stem cells (MSCs) are multipotent cells 
that can be found in several tissues such as bone marrow, 
adipose tissue, synovium, deciduous teeth, umbilical cord 
blood and blood vessels (Awad et al., 2004; De Angelis 
et al., 1999; Lee et al., 2004; Sottile et al., 2002). As they 
are promising candidates for cell therapy, they are used 
as therapeutic agents in experimental models of tissue 
diseases such as osteoarthritis (OA), interstitial lung 
diseases, glomerulonephritis, graft versus host disease 
(GvHD) and myocardial infarction (Kunter et al., 2006; Le 
Blanc et al., 2004; Lee et al., 2006; Minguell and Erices, 
2006; Ortiz et al., 2007; Rodriguez-Merchan, 2014). MSCs 
are a promising cell type for therapy, because they have the 
potential to differentiate into repair tissue and also have 
trophic and immunomodulatory capacities. While they 
have been shown to be capable of improving damaged 
tissue, their contribution does not seem to originate from 
long-term engraftment and differentiation (Toma et al., 
2002; Zhang et al., 2015). This suggests that MSCs can 
also stimulate endogenous tissue repair, in addition to 
their ability to differentiate into cells of the mesoderm 
lineage. The immunomodulatory property of MSCs is 
very useful when inflammation is a major contributor to 
the pathophysiology such as OA (Daghestani et al., 2014), 
rheumatoid arthritis (Komatsu and Takayanagi, 2015) or 
GvHD (Le Blanc et al., 2004). Immune suppression by 
MSCs needs to be induced by pro-inflammatory cytokines 
such as interferon (IFN)γ, tumour necrosis factor (TNF)
α, interleukin (IL)-1α or IL-1β (Groh et al., 2005; Le 
Blanc et al., 2003; Ren et al., 2008). In vitro, MSCs can 
inhibit B cell derived antibody production (Comoli et al., 
2008), generation and function of antigen presenting cells 
(Nauta et al., 2006) or T lymphocyte proliferation and pro-
inflammatory cytokine production (Di Nicola et al., 2002; 
Krampera et al., 2003). In vivo, MSCs were able to reduce 
tissue degradation and inflammation in OA (Daghestani 
et al., 2014), reduce immune activity in autoimmune 
enteropathy (Parekkadan et al., 2008), prolong heart and 
skin allograft survival (Bartholomew et al., 2002; Popp et 
al., 2008) and improve experimental colitis (Gonzalez-Rey 
et al., 2009).
 The mechanisms responsible for MSCs immune 
modulation have been acknowledged to be based on 
paracrine activity. Although it is not precisely known 
which factors cause the effects, it was demonstrated 
that prostaglandin E2 (PGE2) production, indoleamine 
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2,3-dioxygenase (IDO) activity, suppression of nitric oxide 
(NO) production and secretion of cytokines such as IL-6 
(Jiang et al., 2005; Meisel et al., 2004; Nauta et al., 2006) 
can be (partly) responsible. In addition, growth factors such 
as transforming growth factor β1 (TGF-β1) and vascular 
endothelial growth factor (VEGF) (Wang et al., 2008), 
secreted by MSCs, have been shown to influence tissue 
repair and immunological processes (Mallat and Tedgui, 
2002).
 Most studies have considered the immunomodulatory 
properties of MSCs in 2-dimensional (2D) monolayer 
culture (Dominici et al., 2006), as cell expansion is 
necessary to obtain the cell numbers required for therapeutic 
applications. MSCs in monolayer can differ considerably 
in morphology, cell adhesion, cell cycle and differentiation 
from those in 3-dimensional (3D) environments in vitro 
or in vivo (Barminko et al., 2011; Birgersdotter et al., 
2005; Cukierman et al., 2002; Griffith and Swartz, 2006; 
Hansen et al., 1994; Yamada and Cukierman, 2007). Most 
of these studies performed short-term 3D experiments. 
However, for clinical applications, where MSCs therapy is 
aimed at modulating chronic inflammatory reactions, their 
immunomodulatory properties have to be guaranteed for 
at least several weeks in order to improve the pathology.
 The use of alginate might be interesting to retain cells 
at the desired location. Alginate, a natural polysaccharide 
isolated from brown seaweed, is the most common used 
gel for cell encapsulation due to its biocompatibility and 
stability in vivo (de Vos et al., 2002; Shoichet and Rein, 
1996; Wu et al., 2007; Murua et al., 2008). Moreover, 
alginate has the capacity to protect encapsulated cells 
against recognition by the immune system (Barminko et 
al., 2011; Herrero et al., 2007; Kang et al., 2014; Trouche 
et al., 2010; Zanotti et al., 2013), which will enable the use 
of allogeneic cells. This would greatly enhance the clinical 
translatability of MSCs-based therapies.
 In this study using longitudinal imaging, we evaluated 
whether encapsulation in alginate would prolong the local 
presence of allogeneic MSCs in an immunocompetent rat 
and if the cells would maintain their immunomodulatory 
and trophic function for a prolonged period after 
encapsulation.
Materials and Methods
In vivo evaluation of MSCs activity and localisation 
after encapsulation in alginate
Isolation, encapsulation and culture of MSCs
Animal experiments were performed with prior approval 
of the ethics committee for laboratory animal use (protocol 
# EMC116-12-07,5,1).
 MSC-alginate mix was polymerised in 102 mM 
CaCl2 and washed two times in saline. Constructs 
were subcutaneously implanted on the back of sixteen 
weeks old immunocompetent male Wistar rats (Harlan 
Netherlands BV, Horst, The Netherlands). Allogeneic 
bone marrow MSCs from F344 rats (purchased from 
Millipore, Billerica, MA, USA) and xenogeneic human 
bone marrow MSCs were used. Human bone marrow 
derived MSCs were isolated by means of heparinised 
femoral shaft marrow aspirate from patients undergoing a 
total hip arthroplasty (after written informed consent with 
approval of the Medical Ethical Committee of Erasmus 
MC, protocol #MEC-2004-142). Bone marrow aspirates 
were plated in low glucose culture medium (DMEM, 
Dulbecco’s Modified Eagle’s Medium; Gibco, Carlsbad, 
CA, USA) with heat inactivated 15 % foetal calf serum 
(FCS; selected batch Lonza, Verviers, Belgium), 50 µg/mL 
gentamycin (Invitrogen, Carlsbad, CA, USA), 1.5 µg/mL 
Fungizone (Invitrogen), 1 ng/mL FGF2 (Instruchemie B.V., 
Delfzijl, The Netherlands), 0.1 mM vitamin C (Sigma, St. 
Louis, MO, USA) and after 24 h non-adherent cells were 
removed by washing with 2 % FCS in PBS. Adherent cells 
were cultured and upon passaging seeded at a density of 
2,300 MSCs/cm2 and trypsinised (Invitrogen) at sub-
confluence. MSCs from the third to fourth passage were 
used for experiments.
Activity evaluation of long-term encapsulated allogeneic 
MSCs in vivo
To evaluate the retention of viable, encapsulated allogeneic 
MSCs in vivo, we performed bioluminescence imaging 
(BLI) of luciferase transduced F344 MSCs (Fluc-MSCs) 
as described before (Guenoun et al., 2013). 3D MSC-
alginate constructs with 4 × 106 Fluc-MSCs/mL filter-
sterilised 1.2 % low viscosity alginate (Keltone LV, Kelco, 
Surrey, UK) were prepared. The MSC-alginate mix was 
polymerised in a sterilised, custom-designed mould 
consisting of two Durapore membranes (5 µm pore size; 
Millipore) at both sides of a 3 mm thick metal ring (Wong 
et al., 2001). The final cylindrical constructs of 8 mm 
diameter, containing a volume of approximately 151 µL 
and an estimated cell number of 6 × 105 MSCs were made 
with sterile dermal punches (8 mm; Spengler, Hannover, 
Germany). We compared subcutaneous implantation of 
six allogeneic MSC-alginate constructs in one rat with 
six subcutaneous injections of 6 × 105 allogeneic MSCs 
in physiological saline in another rat. The subcutaneous 
immunocompetent rat model is well accepted to study 
biocompatibility and tissue reactions. Moreover, it allows 
reliable longitudinal imaging of luminescence and iron 
oxide particles. Longitudinal cell viability was measured 
by luciferase activity of the transplanted and injected MSCs 
30 min after intraperitoneal (i.p.) injection of 100 µg/
kg of D-luciferine (Promega Benelux B.V., Leiden, The 
Netherlands) using the Xenogen IVIS spectrum (Caliper 
LS, Hopkington, MA, USA) for an emission detection 
time of 10 min. Sensitivity of our BLI was evaluated by 
BLI signal measurements of different amounts of Fluc-
MSCs in vitro (data not shown). Minimum detection limit 
was 50,000 cells/well in monolayer in a 48-well plate. In 
vivo the optimal BLI signal over time was evaluated by 
repeated 10 min imaging after admission of D-luciferine 
up to 1 h. Optimal bioluminescence signal detection with 
BLI was 30 min after admission of D-luciferine. BLI signal 
increased the first 30 min after D-luciferine admission; 
after 30 min the signal remained constant up to at least 1 h. 
Best results were obtained with 10 min BLI measurements 
(integration time 600 s; f/stop 1; binning medium; FOV C). 
In vivo scans were performed 1 d after implantation and 
weekly thereafter for a total of 5 weeks. Optical intensity 
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is reported as arbitrary units. Data were analysed using the 
Living Image version 3.2 software (Caliper LS).
Localisation of long-term encapsulated allogeneic MSCs 
in vivo
To localise the allogeneic MSCs precisely, MSCs were 
labelled with superparamagnetic iron oxide (SPIO) 1 d prior 
to injection/implantation by using ferumoxides 100 µg/
mL medium (Endorem™, Guerbet S.A., Paris, France) 
complexed to protamine sulphate 5 µg/mL medium (LEO 
Pharma N.V., Wilrijk, Belgium) as described previously 
(van Buul et al., 2011). Magnetic resonance imaging (MRI) 
was performed directly after the cell implantation/injection 
to confirm the subcutaneous localisation of the SPIO-
Fluc-MSCs. MR imaging was performed on a preclinical 
7.0T MRI scanner (MR 901 Discovery, Agilent/GE 
Healthcare, Milwaukee, WI, USA) equipped with a 72 mm 
transmit/receive body coil. A fast spoiled gradient echo 
sequence was performed with the following settings: TE/
TR = 1.1/7.3 ms, NEX = 4, FOV = 8 × 6 cm2, acquisition 
matrix = 256 × 192, slice thickness = 1 mm, bandwidth 
= 60 kHz, flip angle = 150°. Sagittal and coronal scans 
were performed to localise the hypo-intense SPIO deposits.
Histological evaluation of the implanted allogeneic MSC-
alginate constructs
5 weeks after implantation/injection, rats were euthanised 
directly after the last scans. The subcutaneous layer of 
the back of the rats, containing all transplanted/injected 
regions, was harvested, separated and scanned individually 
in the MRI to localise the correct injection/transplantation 
regions using the SPIO signal. Samples were fixed in 
0.05 M TRIS buffered saline with 10 % formalin and 
15 mM CaCl2 for 24 h. All samples were embedded in 
paraffin. Sections of 6 µm were sliced and deparaffinised 
before staining. Perl’s iron staining (Klinipath BVBA, 
Duiven, The Netherlands) was performed, according to 
the manufacturer’s protocol, to locate the SPIO-labelled 
MSCs. Perl’s iron staining stained iron particles blue. CD68 
staining was performed on the same sections to identify 
macrophages. Antigen retrieval for CD68 was performed 
through incubation in citrate buffer (10 mM citric acid, 
0.05 % Tween 20, pH 6.0) for 20 min at 90-95 °C. 
Sections were incubated for 1 h with primary antibodies 
for CD68 (#BM4000; OriGene Europe-Acris Antibodies, 
Herford, Germany) diluted to a concentration of 5 µg/mL 
in PBS/1 % BSA (#A7284; Sigma) after blocking of non-
specific binding sites with 10 % goat serum (#0060-01; 
Southern Biotech, Birmingham, AL, USA) in PBS/1 % 
BSA. A secondary biotinylated antibody goat-anti-mouse 
1:50 (HK-325-UM; Biogenex, Fremont, CA, USA) was 
used, followed by incubation with the third antibody 
streptavidin-AP 1:50 (HK-321-UK; Biogenex). Staining 
was then visualised using an alkaline-phosphate substrate 
followed by counter staining with haematoxylin. CD68 
positive cells stained pink.
Evaluation of implanted xenogeneic MSC-alginate con-
structs
To evaluate reproducibility and to improve clinical 
translatability, we encapsulated human bone marrow 
derived MSCs in alginate. 4 × 106 MSCs were mixed in 
1 mL filter-sterilised 1.2 % low viscosity alginate and 
constructs were created by dripping the MSC-alginate 
mixture through a 23-gauge needle in a 102 mM CaCl2 
solution. Five constructs were subcutaneously implanted 
in two different rats for 5 weeks. Additionally, five alginate 
constructs without MSCs were subcutaneously implanted 
in two different rats to evaluate the effect of the alginate 
on the host immune system. 5 weeks after implantation, 
rats were euthanised and transplanted regions were 
harvested. Localisation of the constructs, human bone 
marrow MSCs and host immune reaction were evaluated 
with histological analysis by haematoxylin and eosin (HE) 
and CD68 staining.
In vitro evaluation of MSCs function and survival 
after encapsulation in alginate
Stimulation of immunomodulatory properties
Encapsulated human MSCs, isolated as described above, 
were cultured in DMEM low glucose medium with 2 % 
FCS, 50 µg/mL gentamycin and 1.5 µg/mL Fungizone 
for 48 h. To activate the immunomodulatory properties, 
MSC-alginate constructs were incubated 24 h in DMEM 
low glucose medium with 1 % ITS (BD Bioscience, 
Bedford, MA, USA), 50 µg/mL gentamycin and 1.5 µg/
mL Fungizone supplemented with IFNγ and TNFα (50 ng/
mL each; PeproTech, London, UK), designated as cytokine 
medium. As control, MSCs were cultured in monolayer 
until sub confluency and then incubated with control or 
cytokine medium for 24 h.
 To evaluate long-term function, MSC-alginate 
constructs were pre-cultured for 30 d and subsequently 
stimulated with cytokine medium. Constructs were 
harvested directly after the 24 h stimulation for gene 
expression analyses and medium was harvested and stored 
at −80 °C for analyses of secreted factors.
Gene expression analyses
Alginate was dissolved in 55 mM sodium citric acid 
(Sigma) and spun down for 8 min at 175 × g at 4 °C. 
Cell pellets were resuspended in 1 mL RNABee (Tel-test, 
Firendswood, TX, USA) for RNA isolation. The monolayer 
MSCs cultures in 6-well plates were resuspended in 1 mL 
RNABee. After addition of 0.2 mL chloroform, samples 
were spun down for 15 min at 12,000 × g. Total RNA 
was isolated from the supernatant using the Qiagen RNA 
Micro Kit according to the manufacturer’s instructions 
(Qiagen, Hilden, Germany) and nucleic acid content was 
determined spectrophotometrically (NanoDrop ND1000, 
Isogen Life Science, IJsselstein, The Netherlands). cDNA 
was generated according to manufacturer’s instructions 
using RevertAid™ First Strand cDNA Synthesis Kit 
(MBI Fermentas, St. Leon-Rot, Germany). Gene 
expression analysis was performed using ABI7000 cycle. 
Cycle threshold (Ct) values were corrected by the best 
housekeeper index (BKI), which was calculated by the 
average of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; Fw: ATGGGGAAGGTGAAGGTCG; 
Rv: TAAAAGCAGCCCTGGTGACC; Probe:Fam-
CGCCCAATACGACCAAATCCGTTGAC), ubiquitin 
C  (UBC;  Fw:  ATTTGGGTCGCGGTTCTTG; 
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R v :  T G C C T T G A C AT T C T C G AT G G T )  a n d 
hypoxanthine phosphoribosyltransferase (HPRT; 
Fw: TATGGACAGGACTGAACGTCTTG; Rv: 
CACACAGAGGGCTACAATGTG; Probe: Fam-
AGATGTGATGAAGGAGATGGGAGGCCA).
 RT-PCR primer nucleotide sequences used for IL-6, 
tissue inhibitor of metalloproteinases (TIMP-1), TIMP-2, 
IDO, TGF-β1 and VEGF were described previously (Yuan 
et al., 2014). Relative expression levels were calculated 
using the 2-ΔCt method (Schmittgen and Livak, 2008).
Enzyme-Linked Immuno Sorbent Assay
TIMP-2 and IL-6 protein levels were measured in 
stimulated and non-stimulated MSC-conditioned media 
from three donors by means of ELISA assay according 
to the manufacturer’s protocol (R&D systems, Abingdon, 
UK). All factors were corrected for the amounts present 
in standard MSC culture medium. To determine the 
amount of IDO enzymatic activity in MSC media, the 
level of its metabolite L-kynurenine was measured 
spectrophotometrically as described previously (Kang et 
al., 2008).
Immunomodulation by MSC-alginate constructs
MSC-alginate constructs were co-cultured with activated 
lymphocytes to study their immunosuppressive capacity. 
Therefore, peripheral blood mononuclear cells (PBMCs) 
were isolated from buffy coats of healthy blood donors 
(Sanquin, Rotterdam, The Netherlands) using Ficoll-
Paque™ PLUS (density 1.077 g/mL; GE Healthcare, 
Uppsala, Sweden) separation. Cells were frozen at −150 °C 
until further use in RPMI-1640 medium containing 1 % 
GlutaMAX™-I (Life Technologies, Waltham, MA, USA) 
supplemented with 1 % P/S (Penicillin 10,000 UI/mL, 
Streptomycin 10,000 UI/mL; Lonza), 10 % human serum 
(Sanquin) and 10 % dimethylsulphoxide (DMSO, Merck, 
Hohenbrunn, Germany).
 MSC-alginate constructs containing 4 × 106 cells/mL 
resulted in approximately 3 × 104 MSCs per construct. 2 d 
and 30 d after encapsulation, MSCs were either stimulated 
with cytokine medium or cultured in control medium 
(150 µL/bead) for 24 h. After 24 h constructs were washed 
two times with PBS and transferred per four, two, and one 
bead in a 48-wells plate in triplicate.
 PBMCs were thawed and washed extensively with PBS 
to remove FCS and brought to a concentration of 1 × 107 
cells/mL in PBS and labelled with 1 µM carboxyfluorescein 
succinimidyl ester (CFSE) by quickly mixing followed by 
7 min incubation at 37 °C. Cells were resuspended in RPMI 
medium with 1 % P/S and 10 % FCS and, to stimulate T-cell 
activation, antibodies against CD3 and CD28 (1 µL per 
1 × 106 cells in 1 mL) were added to the suspension with 
a cross-linking antibody (2 µL per 1 × 106 cells in 1 mL) 
(all from BD Biosciences, Bedford, MA, USA). 3 × 105 
stimulated CFSE-PBMCs in 600 µL were added to the 
alginate beads in a 48-well plate. As positive and negative T 
lymphocyte proliferation control, 3 × 105/600 µL stimulated 
and non-stimulated CFSE-PBMCs were cultured in 
triplicate. Stimulated CFSE-PBMCs with 4 empty alginate 
beads (not containing MSCs) were used as baseline control. 
As a positive control for the proliferation inhibitory effect, 
MSCs in monolayer were plated at a density of 1.2 × 105 
MSCs/well in a 48-well plate. After 24 h of attachment 
MSCs were stimulated or non-stimulated with cytokine 
medium for 24 h. After stimulation, cells were washed 
two times with PBS, and 3 × 105 stimulated CFSE-PBMCs 
suspended in 600 µL were added. After 5 d of co-culture, 
PBMCs were retrieved, labelled for 30 min with CD8/CD4 
(BD Biosciences). Cells were analysed by fluorescence-
activated cell sorting (FACS) on a FACS Canto II flow 
cytometer (BD Biosciences). After initial broad selection of 
lymphocytes based on forward and side scatter to exclude 
dead cells and debris, we selected the single CD4+ and 
single CD8+ cells. Proliferation of these cells was analysed 
by decrease of CFSE label.
Characterisation of the encapsulated MSCs
To evaluate if the MSCs maintained their multilineage 
differentiation capacity after 2 and 30 d of encapsulation 
in alginate, the alginate structure was disrupted using 
sodium citrate/ethylene diamine tetra acetate (EDTA, 
Sigma) to release the cells and osteogenic and adipogenic 
differentiation was performed for 21 d. For osteogenic 
differentiation, MSCs were plated at a density of 3 × 103 
cells/cm2 and cultured in high glucose DMEM (Gibco) 
containing 10 % FCS, 10 mM β-glycerophosphate (Sigma), 
0.1 μM dexamethasone (Sigma) and 0.5 mM L-ascorbic 
acid 2 phosphate (Sigma). For adipogenic differentiation, 
MSCs were plated at a density of 2 × 104 cells/cm2 and 
cultured in high glucose DMEM containing 10 % FCS, 
1 μM dexamethasone, 0.2 mM indo-methacin (Sigma), 
0.01 mg/mL insulin (Sigma) and 0.5 mM 3-isobutyl-l-
methyl-xanthine (Sigma). All media contained 50 μg/
mL gentamycin and 1.5 μg/mL Fungizone. Histological 
evaluation was performed with Von Kossa staining (Sigma) 
for osteogenic differentiation and Oil Red O (Sigma) for 
adipose differentiation.
DNA Content
To determinate cell survival after one month of encapsulation 
in alginate we measured DNA content weekly (t = 0, 7, 14, 
21 and 30 d, n = 4 donors). Beads were digested overnight 
at 56 °C in papain digestion buffer (250 µg/mL papain in 
50 mM EDTA and 5 mM l-cysteine hydrochloride; all 
from Sigma). The amount of DNA in each papain-digested 
sample was analysed in the Wallac 1420 victor2 (Perkin-
Elmer, Wellesley, MA, USA) using an extinction filter of 
340 nm and an emission filter of 590 nm by means of an 
ethidium bromide assay (Sigma) with calf thymus DNA 
as a standard (Royce and Lowther, 1979).
Statistics
Statistical analysis of the in vivo BLI data was performed 
by Mann-Whitney U tests. The in vitro T-cell proliferation 
data were analysed in SPSS 21.0 (IBM) by ANOVA with 
Dunnett’s correction using empty beads as control group. 
Analyses of the in vitro data were performed by two way 
ANOVA test using GraphPad Prism 5.00. p < 0.05 was 
considered statistically significant.
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Results
Alginate encapsulated allogeneic MSCs were retained 
in immunocompetent rats for at least 5 weeks.
 To evaluate long-term cell activity, we subcutaneously 
implanted allogeneic rat SPIO-Fluc-MSCs encapsulated 
in alginate and compared this to subcutaneously injected 
SPIO-Fluc-MSCs suspended in saline. MSCs encapsulated 
and MSCs injected were well tolerated without any 
macroscopic sign of inflammation in the immunocompetent 
animals. Clear BLI signal of SPIO-Fluc-MSCs was 
observed directly after both implantation of alginate-cell 
constructs and injection of cells suspended in saline (Fig. 
1 A,B). From 2 weeks onward, injected cells could no 
longer be detected, whereas BLI signal of the encapsulated 
SPIO-Fluc-MSCs in alginate constructs remained clearly 
visible till the end of the study, 5 weeks after implantation 
(Fig. 1 C-E).
 MRI images confirmed the subcutaneous location of 
the six SPIO-Fluc-MSC-alginate constructs and the six 
subcutaneously SPIO-Fluc-MSCs injected regions directly 
after implantation or injection (Fig. 2A,B). For all time 
points, hypo-intense signal from SPIO remained visible on 
MR images. The SPIO signal voids created by encapsulated 
F344 SPIO-Fluc-MSCs became less hypo-intense over 
time but remained comparable in size. The injected cell-
suspension on the other hand generated smaller signal voids 
over time, although intensity remained approximately 
the same (Fig. 2C,D). Histology of the subcutaneous 
transplantation regions was performed at the end of the 
study to confirm presence of implanted cells. Perl’s iron 
staining confirmed the presence of SPIO containing cells 
in subcutaneous regions of encapsulated and injected 
MSCs. In the injected MSCs condition, cells were positive 
for CD68 and Perl’s iron staining, indicating death of the 
MSCs and uptake of the released iron by macrophages 
(Fig. 3A), corresponding to the deceased BLI signal of 
the injected SPIO-Fluc-MSCs. Encapsulated SPIO-Fluc-
MSCs had a viable appearance, were found isolated in the 
alginate and positive for Perl’s iron and negative for CD68 
(Fig. 3B).
 To improve clinical translatability of the allogeneic rat 
MSCs results in vivo, we implanted encapsulated human 
bone marrow MSCs subcutaneously in rats for 5 weeks. 
Transplantation of these xenogeneic MSCs was well 
tolerated without any macroscopic sign of inflammation 
in the immunocompetent rats. Histology confirmed 
the presence of alginate encapsulated MSCs with a 
viable aspect at HE staining (Fig. 3C), without signs of 
macrophage infiltration (Fig. 3D,E). Alginate constructs 
without MSCs did not show ingrowth of host cells or 
macrophage infiltration (Fig. 3F,G). By encapsulating 
allogeneic and xenogeneic MSCs in alginate it was possible 
to retain MSCs in one location for at least 5 weeks in an 
in vivo setting.
MSC-alginate constructs retain long-term 
immunomodulatory capacity in vitro
Expression of immunomodulatory and trophic genes in 
encapsulated MSCs
We evaluated the effect of alginate-encapsulation on 
several properties of human bone marrow derived MSCs. 
To study the immunomodulatory and trophic capabilities 
after encapsulation, MSCs were stimulated for 24 h with 
IFNγ/TNFα after 2 d of culture in alginate. Encapsulated 
MSCs were compared to monolayer cultured cells.
 MSCs encapsulated in alginate constructs responded to 
IFNγ/TNFα very similarly to MSCs cultured in monolayer 
(Fig. 4). Gene expression of IL-6 and IDO (p < 0.05) was 
up-regulated in response to IFNγ/TNFα in both monolayer 
and alginate culture. TGF-β1 was down-regulated in 
all conditions but only reached significance in alginate 
cultures (p < 0.05), whereas VEGF was only significantly 
down-regulated in monolayer cultures (p < 0.05). To 
check whether MSCs in alginate maintained their 
immunomodulatory and trophic response capacity for a 
longer period, we performed 24 h stimulation with control 
and cytokine medium on encapsulated MSCs, which 
had been in culture for 30 d. MSCs retained a response 
to IFNγ/TNFα similar to the 2 d cultured alginate beads 
with up-regulated IL-6 and IDO expression (p < 0.05) and 
down-regulated TGF-β1, TIMP-1 and TIMP-2 expression 
(p < 0.05) while VEGF was not significantly altered (Fig. 
4).
Secretion of immunomodulatory factors by MSC-alginate 
constructs
MSCs cultured in monolayer secreted IL-6 and TIMP-2, 
and expressed IDO activity. MSCs encapsulated in alginate 
for 2 and 30 d secreted IL-6 and TIMP-2, and expressed 
IDO activity as well (Table 1). IDO activity and IL-6 
secretion were increased by IFNγ/TNFα at all time-points, 
Measurement of immunomodulatory factors in conditioned medium of MSCs with or without stimulation by 
inflammatory cytokines IFNg and TNFα for 24 h. MSCs were cultured in monolayer for 2 d (control condition) 
or encapsulated in alginate and cultured for 2 d and 30 d before 24 h of stimulation. IL-6 (pg/mL) and TIMP-2 
(pg/mL) secretion were measured in the conditioned medium by ELISA. IDO enzymatic activity was measured 
spectrophotometrically by means of L-kynurenine level (ng/mL) in the conditioned medium. Mean ± SD is shown. 
n = 3 donors with triplicate samples per donor. a p < 0.05, b p < 0.01 comparing control and cytokine medium. 
Under detection limit, UD.
Table 1. Immunomodulatory factors in conditioned medium of MSCs
2 d monolayer 2 d encapsulation in alginate 30 d encapsulation in alginate
Control Cytokine Control Cytokine Control Cytokine
IL-6 pg/mL 5495 ± 553 53594 ± 3335 a 1650 ± 1271 36044 ± 23304 UD 4148 ± 2439
TIMP2 pg/mL 26181 ± 5099 27750 ± 3917 15541 ± 8027 15291 ± 7669 9483 ± 6913 8635 ± 5518
Kynurenine ng/mL 440 ± 158 13069 ± 1012 b 690 ± 631 11531 ± 102 a 1430 ± 1430 7661 ± 1548 a
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Fig. 1. Long-term cell activity of allogeneic rat SPIO-Fluc-MSCs in vivo in an immunocompetent rat. BLI signal of 
encapsulated allogeneic rat MSCs and injected allogeneic rat MSCs subcutaneously in immunocompetent rats (A,B) 
1 d and (C,D) 5 weeks after implantation/injection. (E) Quantification of BLI signal generated by viable rat SPIO-
Fluc-MSCs up to 5 weeks depicted as arbitrary units: white bars represent encapsulated allogeneic rat MSCs, black 
bars represent injected allogeneic rat MSCs. The 1 week time point was excluded due to a technical failure during 
luciferin injection. 6 × 105 rat MSCs were implanted/injected per location with a total of 6 locations per rat. Mean 
± SD is shown, b p < 0.01. UD = undetectable.
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in accordance with gene expression analysis (albeit IL-6 
did not reach statistical significance in alginate cultures 
due to high donor variation in absolute secretion levels. 
Nevertheless, in all donors IL-6 secretion increased after 
IFNγ/TNFα treatment). The absolute IDO activity and IL-6 
secretion diminished between 2 d and 30 d pre-culture. 
TIMP-2 secretion was not affected by cytokine treatment.
Immunomodulatory effect of MSC-alginate constructs
Immunomodulation by MSC-alginate constructs was 
evaluated by the effect on T lymphocyte proliferation. 
MSC-alginate constructs that were cultured for 2 d 
significantly inhibited proliferation of stimulated CD4+ and 
CD8+ T lymphocytes in a dose-dependent manner (Fig. 
5). Four MSC-alginate constructs (approximately 3 × 104 
cells/bead) 2 d after encapsulation had similar inhibitory 
effect on stimulated T lymphocytes (68 % inhibition for 
CD4+ cells; 52 % for CD8+ cells compared to the control 
with 4 empty constructs; p < 0.05) as the MSCs monolayer 
control (approximately 1.2 × 105 cells per well). This 
effect diminished after 30 d of encapsulation, albeit all 
conditions still inhibited CD4+ T lymphocyte proliferation 
and four MSC-alginate constructs still significantly inhibit 
CD8+-T lymphocyte proliferation (Fig 5; inhibition CD4+ 
proliferation 30 % and CD8+ proliferation 12 % with 4 
constructs). Pre-stimulation of MSC-alginate constructs 
with IFNγ/TNFα for 24 h did not influence the inhibitory 
effects on T lymphocyte proliferation (data not shown).
Fig. 2. Long-term localisation of allogeneic rat SPIO-Fluc-MSCs applied subcutaneously in immunocompetent rats by 
MRI. Oblique views of MR images confirmed the subcutaneous location of the encapsulated allogeneic rat MSCs and 
injected allogeneic rat MSCs (A,B) 1 d after implantation/injection and (C,D) 5 weeks after implantation/injection. Due 
to the different subcutaneous implantation/injection locations, only three pockets can be displayed in a plane image.
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Fig. 3. Histology of the subcutaneous implanted/injected allogeneic and xenogeneic MSCs in immunocompetent rats, 5 
weeks after implantation/injection. (A,B) Implanted/injected allogeneic rat SPIO-Fluc-MSCs were stained with Perl’s 
iron staining (blue), which stains SPIO. CD68 staining (pink) was used to stain macrophages. (A) Injected cells were 
positive for Perl’s iron and CD68 staining suggesting macrophage phagocytosis of SPIO and MSC death, while (B) 
the Perl’s iron and CD68 staining in combination confirmed SPIO labelled MSCs (arrows) encapsulated in alginate 
without CD68 staining. (C) Implanted encapsulated xenogeneic human bone marrow derived MSCs were stained with 
haematoxylin and eosin (HE) staining, which shows isolated MSCs in the alginate with a viable appearance. (D) CD68 
staining was used to identify macrophages and the encapsulated MSCs were negative for CD68. (E) Some macrophages 
were identified in the host tissue around the construct (arrow) without evident macrophage infiltrations. (F) Alginate 
constructs without MSCs were implanted as a control. HE staining showed no cell infiltration in the constructs. (G) 
CD68 staining showed some macrophages in the host tissue surrounding the alginate construct without MSCs (arrow), 
but no evident macrophage infiltrations were found. Haematoxylin and eosin staining (HE), *asterisk indicates alginate 
in B, C, D and F and indicates the location where the alginate was located before processing the sample for CD68 
staining in E and G.
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Fig. 4. Gene expression of immunomodulatory and trophic genes by MSCs with or without stimulation by 
inflammatory cytokines IFNg/TNFα for 24 h. MSCs were cultured in monolayer for 2 d (control condition) or 
encapsulated in alginate and cultured for 2 d and 30 d before 24 h of stimulation. Box and whisker plot 2.5-97.5 
percentile is shown. n = 4 donors with duplicate or triplicate samples per donor. BKI (best house keeper index) 
as average of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ubiquitin C (UBC) and hypoxanthine 
phosphoribosyltransferase (HPRT); Interleukin 6, IL-6; Indoleamine 2, 3-dioxygenase, IDO; Transforming growth 
factor β1, TGF-β1; Vascular endothelial growth factor, VEGF; Tissue inhibitor of metalloproteinases 1, TIMP-1; 
Tissue inhibitor of metalloproteinases 2, TIMP-2; non-stimulated cells with IFNg/TNFα as control, con, stimulated 
cells with IFNg/TNFα for 24 h, stim. a p < 0.05, b p < 0.01, c p < 0.001.
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Long-term retention of MSC properties in alginate
To evaluate their multi-lineage differentiation capacity 
after encapsulation in alginate, MSCs were released after 
2 and 30 d of encapsulation. Adipogenic and osteogenic 
differentiation assays were performed and compared 
with MSCs that were not encapsulated in alginate. The 
released MSCs could still differentiate adipogenically and 
osteogenically, although these differentiation capacities 
were diminished by encapsulation in alginate (Fig. 6 A-F).
 Since we observed a decrease in absolute levels of 
secreted factors and in the inhibition of lymphocyte 
proliferation after 30 d in alginate, we evaluated the 
effect of the alginate encapsulation on MSCs survival 
by measurements of DNA content of the alginate 
constructs after 0, 7, 14, 21 and 30 d of culture. DNA 
content diminished after culture of encapsulated MSCs in 
alginate (p < 0.001), reducing viable MSCs numbers by 
approximately 50 % after 30 d (Fig. 6G).
Discussion
MSCs a re  known to  have  bo th  t roph ic  and 
immunomodulatory properties, which can be used for 
therapeutic applications in regenerative medicine. The 
possibility of using allogeneic cells would reduce costs 
and make it more feasible to guarantee certain qualities of 
the used product, thus increasing the clinical applicability. 
Fig. 5. Inhibition of T lymphocyte proliferation by alginate encapsulated MSCs (approximately 3 × 104 cells/construct). 
Examples of FACS histograms show the fluorescence intensity of (A) non-stimulated CD4+ T lymphocytes stained 
with CFSE; (B) anti-CD3/anti-CD28 stimulated CD4+ T lymphocytes stained with CFSE in the presence of empty 
alginate constructs and (C) anti-CD3/anti-CD28 stimulated CD4+ T lymphocytes co-cultured with 4 MSC-alginate 
constructs. FACS histograms of stimulated (D) CD4+ T lymphocytes and (D) CD8+ T lymphocytes co-cultured with 
one, two and four constructs 2 d and 30 d after encapsulation of MSCs. Mean ± SD is shown. Fluorescence-activated 
cell sorting, FACS; carboxyfluorescein succinimidyl ester, CFSE. Negative control T lymphocyte proliferation, 
non-stimulated; positive controls T lymphocyte proliferation, stimulated; proliferation inhibition control, monolayer 
(approximately 1.2 × 105 cells per well, same cell count as 4 constructs); empty constructs, control (stimulated T 
lymphocytes co-cultured with 4 empty alginate constructs). * indicates statistical significance.
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For a potent effect, in particular in chronic inflammatory 
diseases, cells should remain present locally over a 
certain period of time. Previous studies using stem cell 
tracking methods could not demonstrate the long-term 
presence of these cells after administration in various 
applications (Ankrum et al., 2014; Fischer et al., 2009; 
Gholamrezanezhad et al., 2011; Harting et al., 2009). 
We demonstrated that by encapsulation in alginate, 
active allogeneic and xenogeneic MSCs were retained 
over a period of 5 weeks at the implanted location in 
immunocompetent animals. Moreover, MSC-alginate 
constructs expressed multiple immunomodulatory 
properties and trophic properties in vitro.
 Protection of allogeneic cells against the host immune 
system is important since we aim to use allogeneic MSCs 
to create an “off-the-shelf” therapy. Despite the belief 
that MSCs are immune evasive or privileged (Ankrum 
et al., 2014), MSCs viability is reduced when used in 
inflammatory and immunocompetent environments. 
Furthermore, it is known that cultured MSCs or MSCs 
exposed to inflammatory environments can express major 
histocompatibility complex (MHC)-I and MHC-II. To 
Fig. 6. Osteogenic and adipogenic differentiation of MSCs after encapsulation. Representative pictures are shown. 
(A,C,E) Von Kossa staining was used for osteogenic differentiation with black indicating calcium-phosphate crystals. 
(B,D,F) Oil Red O staining was used for adipogenic differentiation with red indicating lipid drops. (G) Cell survival 
over time in vitro of encapsulated MSCs is measured by DNA content of the beads. Mean ± SD is shown. a p < 0.05, 
b p < 0.01, c p < 0.001 compared to DNA content at t = 0.
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protect allogeneic cells from fast rejection by the immune 
system of the immunocompetent animals, we encapsulated 
them in alginate. Alginate has been used before to protect 
cells against the host immune system (Herrero et al., 2007; 
Kang et al., 2014; Zanotti et al., 2013). Although in our in 
vitro assay, alginate appeared to stimulate the proliferation 
of stimulated T cells, when MSCs were encapsulated, the 
alginate constructs inhibited T cell proliferation. After 
in vivo implantation in an immunocompetent animal, 
encapsulated allogeneic MSCs were detectable with BLI 
for up to 5 weeks, indicating local presence and stable 
viability of the cells. Since no BLI signal of the injected 
SPIO-Fluc-MSCs was detected from 2 weeks onward, 
while the hypo-intense SPIO signal remained visible on 
MRI, we hypothesise that our labelled allogeneic cells died 
and the SPIO was taken up by macrophages. Histology 
showed double stained cells for CD68 and Perl’s iron 
staining, thus endorsing this hypothesis. Similarly, the fact 
that the BLI signal of encapsulated cells remained present 
throughout the study implies that alginate inhibited cell 
death and migration.
 Human MSC-alginate constructs expressed 
immunomodulatory and trophic properties in vitro, even 
after a culture period of 30 d. Although donor variation was 
found, each donor consistently showed upregulation of gene 
expression and secretion of these factors after stimulation 
of the MSCs with inflammatory cytokines. The variation 
between different MSCs cultures could be due to differences 
between donors or between isolated subpopulations or as a 
result of differences introduced during the culture process 
to expand the cells. MSCs were isolated from patients 
undergoing total hip replacement surgery by plating out 
bone marrow on plastic and washing away non-adherent 
cells after 24 h. This isolation protocol is extensively used 
in our laboratory, leading to cell populations with multiple 
MCS characteristics (Farrell et al., 2009; Hellingman et 
al., 2010), but still to a heterogeneous population. These 
effects will be less relevant for application if we can use 
allogeneic cells. In this case, the MSC-alginate constructs 
can be extensively tested before application in patients 
and the most effective MSCs will be selected. For the 
purpose of selection it would be beneficial to know the 
effectors of the MSC-alginate constructs. For this study 
we chose to measure IDO, IL-6, TIMPs, TGF-β1 and 
VEGF as factors secreted by MSCs, since these factors 
are known to play a role in modulating inflammation and 
tissue repair. IDO in MSCs promotes immunosuppression 
(Gerdoni et al., 2007; Matysiak et al., 2008; Ryan et al., 
2005). IL-6 has been reported to have anti-inflammatory 
characteristics (Djouad et al., 2007; Xing et al., 1998), 
as well as pro-inflammatory characteristics (Alonzi et 
al., 1998; Yamamoto et al., 2000). The maintenance of 
TIMP-1 and TIMP-2 gene expression we observed may 
also act locally and control the MMP-induced breakdown 
of extracellular matrix (Vaalamo et al., 1999). TGF-β1 has 
been associated with immune surveillance and immune 
suppression mechanisms (Gorelik and Flavell, 2001; Li 
et al., 2006). Its long-term overexpression leads to severe 
hyperplasia in normal epidermis or oral mucosa (Li et al., 
2004; Liu et al., 2001; Lu et al., 2004). VEGF has been 
reported to have beneficial effects in certain diseases, such 
as myocardial infarction, by contributing as a growth factor 
in the angiogenesis required for tissue repair (Angelo and 
Kurzrock, 2007; Yuan et al., 2014).
 Those molecules are amongst the most frequently 
reported. However, this is only a small fraction of the 
biologically active factors that are secreted by MSCs, 
either soluble or in extracellular vesicles (Bruno et al., 
2015; Lavoie and Rosu-Myles, 2013). It is, therefore, 
important to test the functionality of the secreted factors. T 
cell proliferation tests are the most commonly used for this 
purpose. For the MSC-alginate construct used in this study, 
we found that 2 d after alginate encapsulation, the inhibition 
of CD4+ and CD8+ T lymphocyte proliferation was similar 
to MSCs in monolayer. This indicates that alginate does 
not prevent the secretion of factors important for inhibition 
of T cell proliferation. 30 d after encapsulation in alginate, 
the MSCs were still able to inhibit T cell proliferation. The 
effect was reduced, but still statistically significant, which 
we find encouraging. The data indicate that encapsulated in 
alginate, MSCs have the potential to inhibit HLA class I (by 
CD8+) and class II (by CD4+) mediated T cell responses. 
Our results are in agreement with data showing that MSCs 
suppress the proliferation of CD4+ and CD8+ T cells in 
cell contact but also transwell conditions (DelaRosa et al., 
2009). The inhibition of CD8+ cells can have important 
implications for the use of MSC encapsulated cells in 
immune suppression therapy after organ transplantation. 
It is relevant to mention that pre-stimulation of MSCs with 
IFNγ/TNFα for 24 h did not influence the inhibitory effects 
on T lymphocyte proliferation, which might be explained 
by the fact that stimulated T lymphocytes produce IFNγ 
and TNFα that will stimulate the co-cultured MSCs. These 
findings can have implications for the use of alginate 
encapsulated MSCs in chronic inflammation. In these 
conditions factors such as IFNγ and TNFα will be present 
and in particular CD4+ T cells have been demonstrated to 
play an important role.
 For this study we encapsulated MSCs in alginate 
using a method we have described previously to generate 
cartilage from long-term culture (Pleumeekers et al., 
2014). The MSC-alginate constructs so generated, 
expressed immunomodulatory capacity. This confirms the 
recent studies of Stucky and co-workers, demonstrating 
an inhibition of neuro-inflammation by MSCs that 
were encapsulated in alginate for 1 d, and Gray and co-
workers, demonstrating secretion of factors in reaction 
to inflammatory cytokines after 2 d of encapsulation 
in alginate (Gray et al., 2015; Stucky et al., 2015). We 
demonstrate, in this study, that MSC encapsulated in 
alginate can inhibit T cell proliferation. This capacity, 
however, was reduced after 30 d of encapsulation. This can 
be partly explained by the difference in number of viable 
cells present at 2 d and 30 d after encapsulation. Moreover, 
we cannot exclude that some of cells have changed their 
phenotype. We confirmed whether the MSCs still had their 
multilineage differentiation potential after encapsulation. 
Since our aim was to retain the immunomodulatory 
capacity of the encapsulated MSCs and ,therefore, 
cell differentiation in our construct was not preferred, 
we evaluated extracellular matrix production of the 
encapsulated MSCs in vivo at the end of the experiments 
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by picrosirius red staining. No positive staining for collagen 
was found in the constructs (data not shown) suggesting 
that there was no differentiation of encapsulated MSCs in 
the constructs. Although we did not evaluate the formation 
of glycosaminoglycans, we consider it very unlikely that 
these would be retained in the absence of a collagen matrix. 
Nevertheless, in the long-term small quantities of matrix 
formed by MSCs could possibly influence the secretion 
of immunomodulatory factors and could be playing a 
role in the diminished immunomodulatory effects of our 
constructs observed after 30 d.
 Immediately after encapsulation we typically find 
around 30 % loss of cells. In this study, 50 % of the primary 
encapsulated cells remained viable and the cells did not 
proliferate. Other studies showed higher cell survival after 
encapsulation (Barminko et al., 2011; Duggal et al., 2009), 
which might – among other factors – be explained by 
differences in cell-type used, the amount of serum in culture 
medium or the type of alginate used. Whereas most studies 
used 10 % foetal calf serum for culture, the concentration 
usually used to expand MSCs, we maintained the MSCs 
in low serum medium (2 %), which we considered more 
comparable with the clinical situation after implantation, 
where the availability of nutrients is likely to be restricted. 
The alginate environment and the specific medium used 
might have selected a subpopulation of cells able to survive 
under these conditions. This population however, retained 
the capacity to secrete factors in response to inflammatory 
conditions. Different construct adjustments can be made by 
adjusting the type of alginate, the alginate concentration 
and the construct size, which will influence the integrity 
of the construct and thereby the survival of the MSCs. 
RGD-alginate is known as a good environment for MSC 
survival but since it will stimulate cell attachment it is 
less favourable for preventing host-donor interactions in 
case of allogeneic cells (Duggal et al., 2009; Markusen 
et al., 2006). Binder and colleagues (Binder et al., 2014) 
proposed the co-delivery of alginate with Lysophosphatidic 
acid (LPA) to rescue undifferentiated MSCs from serum 
deprivation and hypoxia-induced apoptosis and thus to 
improve the persistence of undifferentiated MSCs in vivo. 
Although LPA should be used with care, since it is a potent 
mitogen and may contribute to oncogenesis, this indicates 
possibilities for further improvement of the function of 
MSC-alginate constructs.
 The beads can easily be applied during surgical 
procedures. Moreover, it has been suggested that alginate 
beads can be used safely and effectively to deliver stem 
cells percutaneously with minimal loss of viability 
(Abruzzo et al., 2001; Barminko et al., 2011; Duggal et al., 
2009). This holds great promise for use in osteoarthritis, 
tendinopathy, myocardial infarction or acute spinal cord 
injury, amongst others. The construct might require further 
optimisation depending on the final application. For 
application in osteoarthritis, for instance, where the MSC-
alginate beads should be delivered in the joint, the ability 
to withstand mechanical forces in the joint is an important 
pre-requisite that needs attention. Further fine-tuning 
the viscoelasticity of the beads (alginate concentration, 
alginate type, crosslinking) and the size of the beads are 
important material properties to consider in this respect.
Conclusion
In vivo allogeneic and xenogeneic MSC-alginate constructs 
remained locally present at the site of implantation, 
subcutaneously in an immunocompetent rat for at least 
5 weeks. After long-term culture, MSC-alginate beads 
expressed the ability to interactively modulate their 
microenvironment by IDO activity and secreting several 
immunomodulatory and trophic factors such as IL-6, TIMP-
1, TIMP-2, TGF-β1 and VEGF. MSC-alginate constructs 
are therefore an interesting system for application in 
various musculoskeletal diseases with an inflammatory 
component, such as osteoarthritis, tendinopathy or acute 
spinal cord injury. Future studies are needed to show how 
long cells remain encapsulated, to optimise the constructs 
for specific locations of application and to evaluate what 
the effect will be in diseased conditions.
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Discussion with Reviewer
Marphy Murphy: Did the authors check the lungs and 
spleen for MSCs that were injected systemically?
Authors: The main aim of the in vivo study was to 
investigate whether encapsulated MSCs remained 
viable in the same location for a longer time, compared 
to injected cells. We transplanted and injected the 
MSCs subcutaneously, rather than injecting the MSCs 
systemically and during the 5 weeks of follow-up, SPIO 
was seen with MRI at the locations of injection. With 
histology, we found double staining for CD68 and Perl’s 
iron staining at the location of the subcutaneous injection. 
This indicates that the majority of MSCs most likely died 
and macrophages phagocytised the SPIO. We did not check 
the lungs and spleen for MSCs. There is a possibility that 
some MSCs have migrated from the subcutaneous location 
into the vascular system and thereby infiltrate organs, but 
this was not our focus in this study.
Marphy Murphy: 24 h media change following MSCs 
isolation is quite a short time (normally 3-4 d media change 
is used for most of in vitro and cell transplantation work) 
This may have affected experimental outcome compared 
to using a cell population obtained using the standard 3-4 d 
plastic adhesion method.
Authors: This isolation method is extensively used in our 
laboratory and an established method for a long time. The 
MSCs fraction in bone marrow will adhere within 24 h to 
the pre-coated culture plastic. All non-adherent cells such 
as haematopoietic cells and erythrocytes need to be washed 
away to get a clear MSCs isolation. This way we grow 
colonies in the first week that can be used for further cell 
expansion. These cells are being used for chondrogenic, 
osteogenic and adipogenic differentiation. We can indeed 
not exclude that another way of isolating would lead to a 
different cell population.
Editor’s note: The Scientific Editor responsible for this 
paper was Martin Stoddart.
